The market for PCSK9 inhibitors is relatively young, which has (so far) allowed all three approved drug products to grow revenue in each of the last three years. The trio combined for $3.7 billion in revenue in 2024, up from $2.6 billion in 2023 and roughly double the $1.9 billion generated in 2022.

The antibody drug Repatha from Amgen dominates the market with $2.2 billion in global revenue last year. Fellow antibody drug Praluent from Regeneron (United States) and Sanofi (rest of world) delivered a respectable $739 million in 2024 sales, but it's grown "only" 42% since 2022.

Meanwhile, a favorably broad approval in heart disease for RNAi drug Leqvio from Novartis has catalyzed rapid growth in recent years. The genetic medicine generated $754 million in revenue last year, more than double the prior-year total. Leqvio will become the world's first blockbuster RNAi drug product.